Positive data from VOYAGER trial of Crestor (AstraZeneca) for Dyslipidemia patients

Data presented from the VOYAGER study demonstrate the benefits of aggressive statin therapy with Crestor (rosuvastatin), from AstraZeneca, in comparison to atorvastatin and simvastatin in high risk Dyslipidemia patients. VOYAGER is an individual patient data meta-analysis of 32 258 patients from 37 randomised studies, comparing the effects of statin therapy with Crestor (rosuvastatin) to that of atorvastatin and simvastatin. The data suggests that achieving an LDL-C goal of up to 70 mg/dL or more than 50% reduction in LDL-C levels in high risk patients requires aggressive statin therapy. As statin dose increased, a higher percentage of patients achieved these goals, which reflect the latest European Atherosclerosis Society and European Society of Cardiology Guidelines for the Management of Dyslipidaemias. Also, a greater percentage of patients achieved this goal with Crestor than with equal or double doses of atorvastatin or simvastatin. The data are presented at the 2012 European Atherosclerosis Society Congress.